Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension

Starting soon · Not applicable

Conditions studied: PAH

In brief

The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, \>95% v/v), as an adjunct to standard-of-care treatment in patients with pulmonary arterial hypertension (PAH). The expected results are confirmation in humans of our preliminary data, namely a beneficial effect on systemic inflammation and pulmonary endothelial dysfunction in PAH. If our hypothesis is confirmed, omega-3s could constitute a complementary nutritional approach to current PAH therapies, subsequently requiring validation through a larger-scale, randomized, controlled study.

Key facts

Study ID

NCT07697235

Run by

University Hospital, Strasbourg, France

People needed

22

Starts

2026-07-01

Expected to finish

2030-03-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women between the ages of 18 and 75;
• Idiopathic, hereditary, drug-induced, or anorexigen-induced PAH, or PAH associated with connective tissue disease;
• Stable PAH treatment for at least 90 days;
• Subjects capable of understanding the objectives and risks associated with the study and of providing dated and signed informed consent;
• Subjects enrolled in a health insurance plan;
• Subjects who have signed an informed consent form;
• For women of childbearing age: negative pregnancy test at the screening/inclusion visit; effective contraception* throughout the study (recommended in PAH)
• Effective and accepted methods of contraception during the study (subject, partner): oral contraceptive pill, intrauterine device (IUD), condom (male or female). Patients who practice total abstinence do not need to use contraception.

You may not qualify if…

• Patients treated with Omacor®;
• Daily consumption of fish oil or fish oil-based dietary supplements (omega-3);
• Hypersensitivity or allergy to fish, shellfish, peanuts, soy, corn oil, or coconut oil;
• Anticoagulant therapy at therapeutic doses;
• Cardiac decompensation within the month prior to enrollment;
• Other causes of pulmonary hypertension (groups 2, 3, 4, or 5);
• Persistent atrial fibrillation (AF);
• Left ventricular ejection fraction < 45% on echocardiography;
• Recent episode of pulmonary embolism, within the past 6 months;
• Myocardial infarction or placement of a coronary stent within the month prior to enrollment;
• eGFR < 30 mL/min/1.73 m²;
• Malignant disease (not considered in remission);
• Severe sepsis;
• Participation in another clinical trial within the previous 3 months;
• Subjects under legal guardianship, conservatorship, or curatorship

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.